{"info":{"title":{"content":"2024 CSCO指南重磅更新，洛拉替尼获ALK阳性晚期NSCLC一线治疗“I级优先推荐”","en":"2024 CSCO Guidelines Update, Lorlatinib Receives \"Level I Priority Recommendation\" for First-line Treatment of ALK-Positive Advanced NSCLC"},"description":{"content":"*仅供医学专业人士阅读参考2024CSCO指南更新，洛拉替尼获得ALK阳性晚期NSCLC一线治疗\"I级优先推荐\"。为积极...","en":"*For medical professionals only, for reference to the 2024 CSCO guideline update, lorlatinib has been awarded a \"Level I Priority Recommendation\" for the first-line treatment of ALK-positive advanced NSCLC. For the positive..."}},"items":[]}
